Thank you, Lisa and good morning everyone, and thank you for attending today's presentation.
with making please call. forward-looking proceeds company that company be will statements the our note remarks, the Before on today's
statements materially risks actual to these are that These cause could statements. and results those from uncertainties differ projected in to pursuant
including Note cause results Factors More release in company's regarding from forward-looking the to section the issued that filed appear annual XX-K. Form previously under DiaMedica's press Risk results statements in projected in factors the today entitled differ could information, on actual the Cautionary heading and Statement the reports
DiaMedica's our SEC filings are available at www.sec.gov and website. on
also transcript Please XX, speak XXXX comments DiaMedica to duty re-reading. of accurate forward-looking on May only no may today's time longer be disclaims any note call any its that and at update today, or as statements. replay of the made any
a very documents results topline forward on DMXXX ischemic DMXXX We additional provide you to study from for with participants some our stroke. today in Investors stroke suffering are a with release of continue presentation Phase www.diabetic.com. ischemic section the moving today's our copy issued of also from an press study found we plans Yesterday results acute of summarizing to the filed X Both to in share the the excited SEC. and website at our ReMEDy with can the ReMEDy be acute these topline and of the color
Harry Officer, and Scott Medical I'm Financial Chief Dr. Alcorn joined by today our Kellen. Chief Officer,
pancreas the which a KLKX salivary DMXXX treatment protein blood potential local treat in believe plays is vasodilation, critical an several of KLKX system. a the flow oxidative of of are and has a of its system we for the a decreasing managing diseases primarily the where KLKX the role As in kallikrein-kinin It glands. form previously in body. diseases. role requires important the vascular protein we and as in blood kidneys, to produced sufficient recombinant important DMXXX synthetic regulation and positioning and the or stress. discussed, KLKX also very relates as to We of plays healthy the function resistance widening in vessels which inflammation variety activity is
the today's ReMEDy ReMEDy our begin was controlled call a placebo to from experienced ischemic by participants study who reviewing like stroke. topline double-blind, results I'd study. an acute have in
we the During Kailikang, this with ischemic stroke. to used stroke, acute call, currently ischemic the safety primary efficacy KLKX treat consistent term tolerability we in endpoints for The mean when China. while approved also of urine-derived the use stroke and looking were acute signals form
deck share key Turning serious with further supporting the safe safety profile. profile forward. base We evaluates and of to on and derisks you data Slide has regulatory move important adverse potential participants, administered this hurdles DMXXX X, clinical FDA's benefits to are the XXX as positive that safety studies. any analysis slide well summarized no building a your with going we that DMXXX to that demonstrated DMXXX the ReMEDy been events. to screen now with today. over on related was tolerated takeaways are strong allowed path the could forward its our against risks. should lengthen excellent very treatment-related patient Having or an help This us delay is that believe FDA
population looking that stroke closely of most significantly of a resume not means daily treated in are significantly in of with that receive had independent to participants able who XX the that thrombectomy. placebo function. more In full normal participants near participants to thrombectomy we stroke DMXXX DMXXX resembled Secondly, observed or efficacy to a the progressed those This full recovery received participants XX% at group and not who placebo do approximately outperforms than signals, group. people mechanical DMXXX patient target
DMXXX that tPA U.S. administered be in The is can carefully can which XX alteplase recombinant in only in only This drug up a after stroke. half patients is the post selected to administered currently exciting stroke. a four and hours be approved hours particularly within
talk for will tPA and KLKX protein also to human about results the DMXXX approved in stroke. KLK, urine-derived compared We China
In in study, in note strokes kidney and we're excited sharing X participants topline ongoing were protein. course, these is will disease are DMXXX why a significant that we disease had chronic treated kidney rather C-reactive in to we of function. And inflammatory today. with and who addition, to biomarkers be with showed This review of results and reductions you our the because kidney interest our pleased Phase recurrent chronic kidney improvement
action. Turning have and Slide that these of providing X, ReMEDy these the overall mechanism small were observed overview show numbers. based total, believe its of visual In the is high-level protein acts a we in are outcomes charts to a We active study. with of DMXXX results consistent a on a series manner biologically that encouraging in
level The dose the all drug. treatment in that least at this quickly, top resembled based population, that to shows the improvement and corner, DMXXX the starting in recurrent right next received thrombectomy. the excluded closely group patient chart summarize recoveries most are the mechanical note of chart participants that is in one stroke upon that left shows of - target participants on left the To in those our lower this strokes XX% study
eGFR participants of levels treatment. eGFR of below had upon subset three after disease, significant levels in kidney a based chronic showed participants their the DMXXX weeks For mL increase XX which treated
XX meaningful or measure in The days. CRP. reduction treated protein body DMXXX second the inflammation starts with of showed and the row This C-reactive over is participants a
show The are the DMXXX's believe activity with These biomarkers, important last show levels of levels action. treatment. of charts consistent two of oxide weeks which improvements after nitric three we and mechanism EX in prostaglandin two
an as, unmet primarily to that of system. represents X, estimated due number strokes want remind of healthcare ischemic unmet acute XXX,XXX referred U.S. approximately the the The real our of Moving to globally ischemic serious this strokes XX% Slide is care. need that is have quickly million no just each out acute fact AIS occur year. is option. to In stroke XX This seriousness everyone in patients suffering to It which how XXXX, are that of need treatment is AIS. direct or I
X, Slide a have the for summary of design we ReMEDy. On
certain period X third potential XX first every Our to safety study were In X to at efficacy signals. for a mcg/kg The endpoints is primary XX. days. DMXXX assessment of for measured and our a by dose with DMXXX this goal was of IV administered total of followed then mcg/kg day dose participants day
down total were of of some for placebo evenly groups. between characteristics of the Turning XX cohort. baseline to DMXXX participants, and stroke ages, by split present A participants broken X, study genders the Slide average we and severity
received had with note or either both. moment. had will that thrombectomy I'll participants in more about speak mechanical we You TPA large enrolled after number or of a these a treatment they participants
of X, as tolerability or and Slide was to encouraging ReMEDy. summary results, adverse Monitoring Safety present very determined Independent our DMXXX primary for Data by with and the any we The safety Moving absence studies. of the events Board serious a endpoint related prior consistent
patients. believe of upon In profile other DMXXX this regulatory we DMXXX the for for pathway. This study very approval drugs should simplify to evaluation the important addition, and regulatory based benefits derisk potential bodies and further regulatory that risk is were adverse safety and the continued provides our And clinical versus any pretty evaluate FDA future us and as mild. events studies
is. Slide all bathroom, this Can daily people participant. individuals Scoring et living. to The before stroke Ideally of Much the through The let we like a to of the independently. and NIHSS assessment X, attempt or recurrent in Turning Stroke degrees on feed the Can a stroke. around worse fully live at XX, we dress you score results, use are degree the scale, a me Strokes it's of quantify used they cause zero often their scales when or to that by cetera. the they are recovered the is ReMEDy fully to would different score different look the the themselves? themselves? centers walk ability NIH damage impact which post means higher impaired person near to Can they activities the patient the System. achieve where of see of more
on then left most important the in do and on in not the across the the performed least fully There X-X and range scores right the subjectivity The have on evaluate deaths, entire of book improvement between. score subjectivity impacts. of is shift right analysis the authorities. is and more the and individuals the to to recover and many Unfortunately, a amount regulatory of recovery fully an NIH
I'd or reference side study and reduction just also you participants in full is for recoveries score in used in dark improvement being XX, full tPA point score X-X out deaths Slide XX% and NIHSS the approval. can tPA improvements the that show that FDA effects. blue for and X tPA the of demonstrated patient And NIHSS serious of some an a recovery achieving an X. have to
they the is study. represents is the XX One side evaluable comparison participant the XX Slide for first score NIHSS before the using which ReMEDy of for both cohorts dose, withdrew of the participants a in safety to participants number in large the not the the as requirements of the don't due is prior we achieving in full in analysis. participants this of enrollment ReMEDy. placebo inclusion to This receiving level portion recovery. thrombectomy see At large group
to is which device large inserted in presents XX is clot. known but immediately Just only the hospital those the is The participant's blockage more. whose the a navigated the the the arterial cases to it is at vessel, a six remind into in remove procedure up the can which be in clots generally thrombectomy hours, as catheter within or system, procedure some limited patients everyone, to intent with mechanical
to and perform victims U.S. in of is procedure. skilled In X% today, of physician and limitations receive only addition, the about thrombectomy. these needed stroke Because experienced the
DMXXX thrombectomy. an to is not alternative
the thrombectomy were flow. family this or we evaluate us large stroke and and this a combined DMXXX. to for a patients wanted there If have in thrombectomy Personally, in be caused safety by whether sampling eligible if the study to hospital position and of might time, you immediately effect for with included any can These the because blood of beneficial procedure. myself were get when would want you a can procedure to right occlusion my clinical study restore for I vessel participants a in
thrombectomy mechanical In urinary our larger population. plan the anticipated. that include if not was not treated thrombectomy. patient to not than urinary prescribed KLKX. it do much thrombectomy in with We on not top expected That a did KLKX was China understanding is component patient is they is There target our is thrombectomy that receive of
that of focus receive do Our not the procedure. XX% on stroke thrombectomy is victims a
target the NIHSS has patient population here participants thrombectomy enrollment. did for the have scores in group total we to closely XX, are to ReMEDy this receive and analysis. that prior treat Slide a represents DMXXX This to that of participants Turning intended most not XX
a full than positive in differences value a of compelling. XX% to group was small achieved difference. DMXXX near the placebo less full XX% the In recovery p Although or quite number, are participants XX% as the a compared group, The visually the X.X.
a dose reduction the those being administered dramatically results window occurred only within deaths hours longer also showed to results of group. tPA of a The selected. be to selectively within patients compared four treatment the stroke stress group XX-hour a and that placebo XX% to window with in in compared DMXXX participants the therapeutic half that I DMXXX first must can't and number a enough
hospital stroke most the participants care the do therapy. palliative the stroke when the XX receiving eligible exclude Also enrollment group prior that be participants hours those and only, placebo receiving to note believe of can victims we for and results get to limiting similar. to a are that We within tPA
the We some Modified results see scores. also with Rankin
safety the to Slide tPA show the KLKX are profile here therapeutic believe X tPA offering a the what window XX, seeing and be recombinant approved longer studies KLKX, while results we in compared and comparison Asia. results in we DMXXX compared form message Kailikang, is a and for of key urinary much On to want The that comparable results Activase, much tPA. improved Phase of will to a we urinary improved the you and Kailikang
please. XX Slide
one from improvements DMXXX showing the placebo the participant's observations the with recurrence strokes On other from abilities, data. group. we four to we're Beyond functional are resulting and of this in slide severe participant very seven in also reduced deaths study recurrence the in group placebo in encouraged by
XX the upon thrombectomy. which based are group results participants These safety in receiving the participants include
recurrence. As you significant that a published clear are stroke with studies can These see, results the with urine the consistent in have reductions difference. shown KLKX
has DMXXX these why we key aside, are an results in reason the potential to thrombectomy neoadjuvant believe future. the an for As therapy a be patients
of important We that effects XX, blood this their in with decrease at also CKD in DMXXX the in considered interested With of group. participants mechanism DMXXX is an consistent at we our CRP the of marker also On we're observed CKD, in stroke. looking with action. show inflammation the Slide believe DMXXX's of time interest the on
the kidney of also stroke and disease. not diseases stroke Although chronic associated patients with KLKX. understood, CKD have relationship low both well also are do between is levels We believe many
to Slide function. On participant eGFR in baseline of XX at with changes patients filtration into participants day eGFR that XX looked mid-XXs participants This in for DMXXX the receiving eGFR the and an day any was pleased kidney rate With glomerular XX, mL XX average primary XX dosing entry after measure respect the X.X the of participants estimated than increase range. at in days is to mL eGFR. in study are at the showed the see average significantly better below study. group. an had XX XX placebo a we we eGFR These participants at a or
in group is very discontinued. DMXXX. this potential of treatment a XX, with the early DMXXX level This could retained be that days signal. the higher is a Equally at of an a use observed that after we of number associated this day positive small encouraging, eGFR sign benefits participants, but retained Note XX participants
slightly to different in proportion to it On who at a the we patients eGFR down XX, in compared had Slide way. broke look of increase placebo
in occurred results Here that effects the least XX% outliers. This mL show that DMXXX of experienced the a wasn’t number driven the increase at small a participants of eGFR. and X shows the broadly average by
almost as placebo but was summarizes the in in initial group, elevated DMXXX liter chart lowered blood benefit in per DMXXX at change participants with in continued group. diabetes, in levels glucose who X XX those glucose to levels levels Slide elevated DMXXX reductions On glucose are we at blood baseline. development had by blood XX day glucose pleased the not At This XX. see day mm/L
Lastly, on nitric to critical releases of which prostaglandins. mechanism of XX, KLKX normal and or the restore two levels oxide bradykinin DMXXX hormones, is Slide
significant As these you can much to demonstrated improvements here, see Again, encouraging DMXXX than activity. versus baseline, the us, of DMXXX group. placebo are groups the better signals
very that's no adverse smooth that serious more DMXXX To tolerated safety today's presentation, building is paths please. to as recap as positive important we've a our XX Slide seen related was to with DMXXX events possible. commercialization make and profile and predictable
placebo were when not We've significantly for that most hours the the seen stroke U.S. the thrombectomy mechanical results DMXXX. receive of is their in drug also the the which resemble XX approved that drug stroke for group being that to patient up than based treatment in administered XX% times tPA, upon population approximately these stroke. stroke post longer six DMXXX Further patients Approximately only excluding outperformed patients did target DMXXX to group closely
results reviewed in U.S. the data in to improved the how from alteplase, compared Kailikang recombinant also We tPA China. the product DMXXX's studies for and Phase X
we we for treatment have participants results. in I reviewed severe related also fairly showed our reductions topline to significant not of that want highlight our study. kidney development of because negative the to data that disease We disease, of course, DMXXX any with DMXXX stroke, represents with patients. improvements function. this in critical study recurrent also in treated chronic ReMEDy the And strokes, data positive Lastly, in kidney factor were results data seen believe of stroke a concurrent the of for chronic kidney the
while tight for also our economists stroke discipline meeting of therapy DMXXX continuing Phase with focus Turning stroke and study health discuss future accelerated do the in on Phase treatment intend plan design to payers to to results, chronic the potential X designations. We fiscal request regulators kidney this in prepare to next the breakthrough completing study. maintain and ReMEDy evaluate We to and partnerships intend for to what's for disease. engage study We intend to briefly stroke. potential XX, so Slide requirements parallel. REDUX a We strategic here's review and to advisors, further and X/X for
Now Dr. the on to call brief Harry turn let a REDUX the for update trial. me over Alcorn,
